Abstract

BackgroundA partial deficiency in Protoporphyrinogen oxidase (PPOX) produces the mixed disorder Variegate Porphyria (VP), the second acute porphyria more frequent in Argentina. Identification of patients with an overt VP is absolutely important because treatment depends on an accurate diagnosis but more critical is the identification of asymptomatic relatives to avoid acute attacks which may progress to death.MethodsWe have studied at molecular level 18 new Argentinean patients biochemically diagnosed as VP. PPOX gene was amplified in one or in twelve PCR reactions. All coding exons, flanking intronic and promoter regions were manual or automatically sequenced. For RT-PCR studies RNA was retrotranscripted, amplified and sequenced. PPOX activity in those families carrying a new and uncharacterized mutation was performed.ResultsAll affected individuals harboured mutations in heterozygous state. Nine novel mutations and 3 already reported mutations were identified. Six of the novel mutations were single nucleotide substitutions, 2 were small deletions and one a small insertion. Three single nucleotide substitutions and the insertion were at exon-intron boundaries. Two of the single nucleotide substitutions, c.471G>A and c.807G>A and the insertion (c.388+3insT) were close to the splice donor sites in exons 5, 7 and intron 4 respectively. The other single nucleotide substitution was a transversion in the last base of intron 7, g.3912G>C (c.808-1G>C) so altering the consensus acceptor splice site. However, only in the first case the abnormal band showing the skipping of exon 5 was detected. The other single nucleotide substitutions were transversions: c.101A>T, c.995G>C and c.670 T>G that result in p.E34V, p.G332A and W224G aminoacid substitutions in exons 3, 10 and 7 respectively. Activity measurements indicate that these mutations reduced about 50% PPOX activity and also that they co-segregate with this reduced activity value. Two frameshift mutations, c.133delT and c.925delA, were detected in exons 3 and 9 respectively. The first leads to an early termination signal 22 codons downstream (p.S45fsX67) and the second leads to a stop codon 5 codons downstream (p.I309fsX314). One reported mutation was a missense mutation (p.G232R) and 2 were frameshift mutations: c.1082insC and 1043insT. The last mutation was detected in six new apparently unrelated Argentinean families.ConclusionMolecular analysis in available family members revealed 14 individuals who were silent carriers of VP. Molecular techniques represent the most accurate approach to identify unaffected carriers and to provide accurate genetic counselling for asymptomatic individuals. The initial screening includes the insertion search.

Highlights

  • A partial deficiency in Protoporphyrinogen oxidase (PPOX) produces the mixed disorder Variegate Porphyria (VP), the second acute porphyria more frequent in Argentina

  • Variegate Porphyria (VP) (MIN # 176200) is an autosomal dominant disorder associated with a deficiency of the penultimate enzyme of the heme biosynthetic pathway [1,2,3] the Protoporphyrinogen oxidase [PPOX; EC 1.1.3.4, Genebank accession number X99450.1] which catalyses the six-electron conversion of Protoporphyrinogen IX to Protoporphyrin IX (PROTO IX) (Figure 1)

  • Acute attacks may frequently result from exposure to diverse porphyrinogenic drugs, alcohol ingestion, reduced calories intake due to fasting or dieting, infections and hormones which stimulate heme synthesis by δ-aminolevulinic acid synthase (ALA-S) induction thereby increasing the production of the porphyrin precursors ALA and porphobilinogen (PBG) [3,4,5]

Read more

Summary

Introduction

A partial deficiency in Protoporphyrinogen oxidase (PPOX) produces the mixed disorder Variegate Porphyria (VP), the second acute porphyria more frequent in Argentina. The hereditary porphyrias are a group of diseases resulting from genetically determined partial deficiencies in one of the heme biosynthetic enzymes. These disorders can be classified on the basis of their clinical manifestations into cutaneous, acute and mixed porphyrias. Variegate Porphyria (VP) (MIN # 176200) is an autosomal dominant disorder associated with a deficiency of the penultimate enzyme of the heme biosynthetic pathway [1,2,3] the Protoporphyrinogen oxidase [PPOX; EC 1.1.3.4, Genebank accession number X99450.1] which catalyses the six-electron conversion of Protoporphyrinogen IX to Protoporphyrin IX (PROTO IX) (Figure 1). Acute attacks may frequently result from exposure to diverse porphyrinogenic drugs, alcohol ingestion, reduced calories intake due to fasting or dieting, infections and hormones which stimulate heme synthesis by δ-aminolevulinic acid synthase (ALA-S) induction thereby increasing the production of the porphyrin precursors ALA and porphobilinogen (PBG) [3,4,5]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call